Ann: Appendix 4C September 2021, page-53

Yeah, this has been my rationale for a while. Bodyguard and Reduit will be known quantities by the time the options expire. If the products fail, I think the only way the company can continue is with another total transformation, in which case it will no longer look much like the company it is today. I personally have my doubts about reduit, but I still reckon there's a chance lubricen could turn into a big hit. Those clinical trial results looked good, and there's a huge, fairly desperate market out there for such a product.